BeiGene, Ltd. (BGNE)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE). Investors who purchased BeiGene securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether BeiGene has violated federal securities laws.
On June 15, 2023, Morningstar published an article entitled “BeiGene shares drop after AbbVie unit files patent infringement lawsuit over cancer drug.” The article stated, “AbbVie’s (ABBV) Pharmacyclics unit filed a patent-infringement lawsuit against the biotech company. BeiGene’s manufacture and sale of Brukinsa for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma infringe on Pharmacyclics’ patent for Imbruvica, which treats the same conditions, Pharmacyclics alleged in the complaint filed Tuesday in federal court in Delaware. Brukinsa in January received U.S. Food and Drug Administration approval for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.” Following this news, BeiGene American Depositary Shares (“ADS” or “ADSs”) dropped $7.08 per share, or 3.4%, to close at $201.04.
If you are aware of any facts relating to this investigation or purchased BeiGene shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.